to X. Please John. Slide you, turn Thank
have we've was better 'XX a allowing focus and position I'd changes today's key these us a made many well into learned with the John explained, to 'XX, that update as significant change as to in how covet each stronger to XXXX lessons plan As season. lessons of for for ourselves year our a on commercial are our like translate grow to we we regions action our strategy. to vaccination share business, goal of
turn to Please X. Slide
the I'd Full which XXXX in sales quarter. like Canada, the includes fourth and XX% $XXX $XXX million from million, APA XXXX Korea on were to sales the product Europe, that opportunities context in from First, remainder of Over and of U.S., high-level provide XXXX. came our product Singapore, some in Taiwan sales markets. year Australia, the
deliveries XXXX contract value expected through entered for outstanding in XXXX APA we Importantly, $X over planned with with billion XXXX.
for BB APA Europe X our Zealand regulatory the XXXX, sales product deliveries for approval. New Australia and Hemisphere to APA Southern upon QX For include and and sales then remaining
private CDC year for and We also XX for is the on additional to discuss dose springtime market ACIP as U.K. individuals well over, the incremental an which as opportunity see recommend meeting potential today. for the to this in
Please turn to Slide X.
several As John first our our under timing vaccine in was agreements. and a APA XXXX, U.S., dose learned the U.S. X commercial related lot which for mentioned entry, regulatory In competing and to world post-pandemic gain our our earlier, key successfully in We authorization and product made markets market to ability factors year secured impacted in share. dynamic we a market. our updated presentation approval to our significant market the around deliveries
vaccinations fact control, for over disappointing our million at led XX channel the that of our accounted performance retail namely and doses outside However, factors U.S. XX% size to also market the COVID of expectations. just the below over
outlets, continue much a for levels We significant achieved Novavax. better in uptake, U.S. in the and in first retail awareness carried an we when we aided processes some availability. and saw to that of U.S., that for for important have opportunity the believe pockets we performance market of seen were up time share We In opportunity market some XX% on to the where provide XXXX. rapid U.S. holds should over built even an the milestones awareness XX%
start market in the early on which focused season. of anticipate are we the vaccination XXXX, in September, For as being we
drove also streamlined so season, the and and Today, major pharmacy top focus updated in the built a overwhelmingly setting We pharmacies, retail XX% the full vaccine the leveraging in customer season. the first expanded already relationships intend know retailers to offer recalibrated licensure. vaccination we our who took our that at potentially in the are last engagement under the BLA national We prefilled season syringe access and negotiating stage COVID currently vaccinations this teams table in change. for approved, to if our to with are have of business on past and top channel. we regional place post-pandemic this
September market if a BLA believe we can delivery, approval, we share. improved secure syringe early we that Additionally, prefilled and a achieve meaningfully
the opportunity segment, last had shots convert which see our season, plan concentrate and and of an We especially market XX-plus to is and rates this Novavax promotional to in that XX% vaccination vaccine we arms. highest effort where the to spend
vaccination XX for We the those vaccine. also groups result meeting ACIP are increased high-risk updated including for potentially from benefit over our recommendation spring today, opportunity and in watching to will a which closely
FDA important our working on-time of we the objective submission closely with are delivery of are Finally, we making also on on BLA. a rolling progress our
turn Slide X. to Please
starting Now markets Europe let's converts year outside a commercial the for time. market the which talk this with first U.S., about to
see timely we in market first our time strong and Commission markets, which include as single mRNA our our a the for The its dose now U.K. ended on revenue France for underway to pressure these planning focus U.K. of green health Italy, a recently APA be vaccine and for and from are commercial are with will the Our Nuvaxovid. leading private potential despite in in the as the a retailers Spain we in entering Agency we APAs, featuring book providers. with availability. In the discussions In and XXXX market Security presentation are European vaccine updated and opportunity competitive launch well Health in Nuvaxovid delivering occupational
already seeing our for potential interest orders are Nuvaxovid We in vaccine.
well APA Asia in Overall, and under Pacific expected global on next the deliveries remain remains New us focused as Australia X for for the Pacific, largest Asia efforts commercial our through Taiwan. market in opportunity seasons Zealand, Finally, Singapore and APAs. existing as our an
We Australia New and dated Zealand vaccine soon. approval of expect in our
providers Finally, par on of our awareness APA, and our Canada, with mRNAs with consumers. our differentiated on care recommendation and to vaccine health driving execute we in continue NAS
XX. to turn Slide please Now
many we markets. scope we working execution significant John how singularly Across the all in coordinate operational commercial As to for organization to a noted, key all to and have key to critical fall are streamlining successful remain scale focused for our season needed our how our regulatory and our to 'XX-'XX of season. upcoming areas coordinating ready work, tirelessly we for and CMC be our the the to activities on our to processes and changes made efforts, we are workflows
that We indicates of data Nuvaxovid Europe and continue and the vaccine to rest that believe Nuvaxovid's and world. is the significant there the demand U.S. our for protein-based
as business expect product next and in contribute with to As we error transformation our APA seasons mix and we and their the future, commercial mature agreements total the revenue over Novavax' to reach to continuing on focus grow pandemic sales X conclusion now between the XXXX. continued sales
vaccines, We believe is and that seasonal for towards COVID. flu market combination the migrating respiratory especially
of convert think to And we of over combo market is believe non-mRNA that the shows XX% care research half option. providers market We to like candidate are our consumers of data. with flu development. proven by XX% capture opportunity. to flu vaccine a To other vaccine are positioned COVID combination well protein-based technology our and platform, we together this updates, bringing products Matrix-M date, that to hand positive key to to discuss outstanding fair Filip. ahead to would prefer anticipated at and and Our III other over Phase in we I share adjuvant, it of product and market R&D competition health an
